Leukemia Research
Volume 27, Issue 9 , Pages 783-788 , September 2003

Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan

  • Takashi Shimamoto

      Affiliations

    • First Department of Internal Medicine, Tokyo Medical University, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-3-3342-6111; fax: +81-3-5381-6651.
    • ,
  • Kaoru Tohyama

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Takahiro Okamoto

      Affiliations

    • Second Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Takashi Uchiyama

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Hiroyuki Mori

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Masao Tomonaga

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Yoshinobu Asano

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Yoshiyuki Niho

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Masanao Teramura

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Hideaki Mizoguchi

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Mitsuhiro Omine

      Affiliations

    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan
    • ,
  • Kazuma Ohyashiki

      Affiliations

    • First Department of Internal Medicine, Tokyo Medical University, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
    • The Japanese Study Group for Intractable Hematopoietic Diseases, Hyogo, Japan

Received 23 August 2002 ,Accepted 20 December 2002.

References 

  1. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Sem. Hematol. 1996;33:150–162
  2. Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H, et al.  Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int. J. Hematol. 1997;66:345–351
  3. Economopoulos T, Ecomonidou J, Giannopoulos G, et al.  Immune abnormalities in myelodysplastic syndromes. J. Clin. Pathol. 1985;38:908–911
  4. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. Br. J. Haematol. 1986;63:143–147
  5. Baumann MA, Milson TJ, Patrick CW, Libnoch JA, Keller RH. Immunonoregulatory abnormalities in myelodysplastic disorders. Am. J. Hematol. 1986;22:17–26
  6. Merchav S, Nagler A, Silvian I, Carter A, Tatarsky I, Spira G. Immunogloblin synthesis in myelodysplastic syndromes: normal B-cell and immunoregulatory T-cell functions. Clin. Immunol. Immunopatol. 1987;42:195–201
  7. Colombat PH, Renoux M, Lamagnere J, Renoux G. Immunologic indices in myelodysplastic syndromes. Cancer. 1988;61:1075–1081
  8. Symeonidis A, Kourakli A, Katevas P. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur. J. Haematol. 1991;47:277–281
  9. Billströem R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes—clinical and cytogenetic features. Eur. J. Haematol. 1995;55:42–48
  10. Enright H, Jacob HS, Vercelloti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br. J. Haematol. 1995;91:403–408
  11. Culligan DJ, Whittaker CJ, Jacobs A, Pauda RA. Clonal lymphocytes are detectable in only some cases of MDS. Br. J. Haematol. 1992;81:346–352
  12. Tsukamoto N, Morita K, Maehara T, et al.  Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br. J. Haematol. 1993;83:589–594
  13. Young NS, Barrett AJ. The treatment of acquired aplastic anemia. Blood. 1995;85:3367–3377
  14. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS. Anti-thymocyte globulin for patients with myelodysplastic syndrome. Br. J. Haematol. 1997;99:699–705
  15. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548–1551
  16. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol. 1998;100:304–309
  17. Shimamoto T, Iguchi I, Ando K, Katagiri T, Tauchi T, Ito Y, et al.  Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br. J. Haematol. 2001;114:358–361
  18. Asono Y, Maeda M, Uchida N, Yokoyama T, Osaki K, Shimoda K, et al.  Immunosuppressive therapy for patients with refractory anemia. Ann. Hematol. 2001;80:634–638
  19. Greenberag P, Cox C, LeBeau M, et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  20. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  21. Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S, Matsuda T, et al.  Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporin-dependent aplastic anemia. Blood. 1994;84:4257–4261
  22. Hashimoto M, Kinoshita T, Yamasaki M, Tanaka H, Imanishi T, Ihara H, et al.  Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens. 1994;44:166–173
  23. Okamoto T, Okada M, Yamada S, Takatsuka H, Wada H, Tamura A, et al.  Good response to cyclosporin therapy in patients with myelodysplastic syndromes having the HLA-DRB1∗1501 allele. Leukemia. 2000;14:344–346

PII: S0145-2126(03)00008-0

doi: 10.1016/S0145-2126(03)00008-0

Leukemia Research
Volume 27, Issue 9 , Pages 783-788 , September 2003

Article Tools